Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

NCT01423149 | Completed Phase 2 DMC

• 1 other identifier: MMD-213
• Study Type: interventional
• Target: 23
• Locations: 0 countries
• Sites: N/A

Brief Summary

The objectives of this study are to evaluate the safety and efficacy of 3 dose groups (27, 36 and 45 mg/m2) of Combretastatin A-4 Phosphate for the treatment of subfoveal choroidal neovascularization in subjects with pathologic myopia.

Conditions

Choroidal Neovascularization; Myopia, Degenerative

Keywords

subfoveal choroidal neovascularization; pathologic myopia

Outcome Measures

Primary Outcomes (2)

• Visual acuity line change from baseline at 3-month following

  from baseline to 3 months

• Visual acuity response category at 3-month follow-up

  from baseline to 3 months

Secondary Outcomes (3)

• Visual acuity line change from baseline at 1 month follow-up

  from baseline to 1 month

• Visual acuity response category at 1 month follow-up

  from baseline to 1 month

• Number of patients with treatment emergent adverse events

  from first dose of study drug to 30 days after last dose of study drug

Study Arms (3)

36 mg/m2 Combretastin A-4 Phosphate

EXPERIMENTAL

Drug: Combretastatin A-4 Phosphate

45 mg/m2 Combretastatin A-4 Phosphate

EXPERIMENTAL

Drug: Combretastatin A-4 Phosphate

27 mg/m2 Combretastatin A-4 Phosphate

EXPERIMENTAL

Drug: Combretastatin A-4 Phosphate

Interventions

Combretastatin A-4 Phosphate DRUG

Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.

Also known as: CA4P, fosbretabulin

27 mg/m2 Combretastatin A-4 Phosphate; 36 mg/m2 Combretastin A-4 Phosphate; 45 mg/m2 Combretastatin A-4 Phosphate

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Provide written informed consent
• Be able and willing to follow instructions
• Age 18 to 50 years old (inclusive)
• Have area of CNV within 50 um or under the geometric center of the foveal avascular zone Have greatest linear dimension of lesion 5,400 um or less, with \>/=50.0% of the lesion composed of CNV (features which obscure the boundaries of the CNV such as blood, serous pigment epithelial detachment or blocked fluorescence must occupy \<50.0%) as confirmed by Doheny Image Reading Center (DIRC)
• Have best corrected distance visual acuity (ETDRS) of 20/20 to 20/200 (LogMAR +0.0 to 1.0), inclusive in the qualifying eye(s)
• Have pathologic myopia presenting - 6.0 diopters or more correction required OR an axial length of the \>/= 26.5 mm
• Be able and willing to avoid any medication that the investigator feels may interfere with the study
• If female and of childbearing potential, agree to submit a sample for pregnancy testing and have a negative pregnancy test within 1 day prior to each treatment. Females are considered of childbearing potential unless they are surgically sterile or post-menopausal for 12 months. Females of childbearing potential must agree to an approved form of contraception for the duration of the study.

You may not qualify if:

• Have contraindications, allergies or sensitivity to the use of the study medications
• Have clinical signs or symptoms, in the opinion of the investigator, that may interfere with the study
• Features of any condition other than pathologic myopia associated with CNV, such as age-related macular degeneration
• Have a tear of the retinal pigmented epithelium
• Have undergoing ocular therapy/surgery or major surgery in the last 3 months or have any surgeries planned during the study period
• Have any significant illness or condition, ocular or systemic that could, in the opinion of the investigator, be expected to interfere with the study
• Have angina (stable or severe, even if controlled with medications), 6 months S/P myocardial infarction ,congestive heart failure, history of or presence of any clinically significant supraventricular or ventricular arrhythmias or syncope episodes
• Have ECG with QTc \>450 msdec or other clinically significant abnormalities such as left bundle branch block, left ventricular hypertrophy, etc.
• Have uncontrolled QTc prolongation
• Take any drugs known to prolong the QTc interval however subject can remain eligible if a non-QTc substitute can be administered
• Have uncontrolled hypertension (defined as blood pressure consistently greater than 150/100 mm Hg irrespective of medication)
• Uncontrolled hypokalemia and/or hypomagnesemia
• Have symptomatic peripheral vascular disease or cerebrovascular disease
• Have psychiatric disorders or other conditions rendering subjects incapable of complying with the requirements of the protocol
• Be receiving concurrent hormonal therapy with exception of Gonadotropin-releasing hormone agonists in subjects with hormone refractory prostate cancer, hormone replacement therapy, oral contraceptive, and megestrol acetate used for anorexia/cachexia

Sponsors & Collaborators

• Mateon Therapeutics: lead

Related Publications (1)

• Giri P, Batra PJ, Kumari A, Hura N, Adhikary R, Acharya A, Guchhait SK, Panda D. Development of QTMP: A promising anticancer agent through NP-Privileged Motif-Driven structural modulation. Bioorg Med Chem. 2023 Nov 15;95:117489. doi: 10.1016/j.bmc.2023.117489. Epub 2023 Oct 5.

  PMID: 37816266 DERIVED

MeSH Terms

Conditions

Choroidal Neovascularization; Myopia, Degenerative

Interventions

fosbretabulin

Condition Hierarchy (Ancestors)

Choroid Diseases; Uveal Diseases; Eye Diseases; Neovascularization, Pathologic; Metaplasia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Myopia; Refractive Errors

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 22, 2011
• First Posted: August 25, 2011
• Study Start: March 1, 2005
• Primary Completion: January 1, 2007
• Study Completion: January 1, 2007
• Last Updated: November 1, 2011

Record last verified: 2011-10